UNITED STATES JUDICIAL PANEL on MULTIDISTRICT LITIGATION

IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION

MDL No. 2750

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO -1)

On December 7, 2016, the Panel transferred 18 civil action(s) to the United States District Court for the District of New Jersey for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. See _F.Supp.3d_ (J.P.M.L. 2016). Since that time, no additional action(s) have been transferred to the District of New Jersey. With the consent of that court, all such actions have been assigned to the Honorable Brian R. Martinotti.

It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the District of New Jersey and assigned to Judge Martinotti.

Pursuant to Rule 7.1 of the <u>Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation</u>, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the District of New Jersey for the reasons stated in the order of December 7, 2016, and, with the consent of that court, assigned to the Honorable Brian R. Martinotti.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of New Jersey. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7—day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is pending at this time, the stay is lifted.

Dec 19, 2016

CLERK'S OFFICE
UNITED STATES
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:

Jeffery N. Lüthi Clerk of the Panel

IN RE: INVOKANA (CANAGLIFLOZIN) PRODUCTS LIABILITY LITIGATION

MDL No. 2750

SCHEDULE CTO-1 - TAG-ALONG ACTIONS

<u>DIST</u>	DIV.	<u>C.A.NO.</u>	CASE CAPTION		
CALIFORNIA CENTRAL					
CAC	5	16-02020	Lois Mercado v. Janssen Research and Development, LLC et al		
FLORIDA NORTHERN					
FLN	5	16-00281	KAMPE v. JANSSEN PHARMACEUTICALS INC		
ILLINOIS CENTRAL					
ILC	1	16-01406	Cape v. Janssen Ortho LLC et al		
ILLINOIS NORTHERN					
ILN	1	16-09441	Faedtke v. Janssen Pharmaceuticals, Inc.		
ILLINOIS SOUTHERN					
ILS	3	16-01140	Klein v. Janssen Pharmaceuticals, Inc.		
KENTUCKY EASTERN					
KYE	0	16-00065	Moore et al v. Janssen Research & Development, LLC et al		
KENTUCKY WESTERN					
KYW	3	16-00658	Tindle v. Janssen Pharmaceuticals, Inc. et al		
LOUISIANA EASTERN					
LAE	2	16-16678	Vetter v. Janssen Pharmaceuticals, Inc. et al		
MISSOURI EASTERN					
MOE	4	16-01707	Grubbs-Williams et al v. Janssen Pharmaceuticals, Inc. et al Opposed 12/19/16		

Case 2s2610V-2024167V-20241167V1Dloc Dioneum 120t 17/le 0File2d 192/1139/176ag Page 133 of 3

MOE	4	16-01766	Seamon v. Janssen Pharmaceuticals, Inc. et al		
NEVADA					
NV	2	16-02417	Nockowitz v. Janssen Pharmaceuticals, Inc., et al		
OHIO NORTHERN					
OHN	1	16-02476	Carlson et al v. Janssen Pharmaceuticals, Inc.		
TENNESSEE EASTERN					
TNE	1	16-00407	Ryan v. Janssen Pharmaceuticals, Inc. et al		
TENNESSEE MIDDLE					
TNM TNM	3	16-03052 16-03053	Adams v. Janssen Pharmaceuticals, Inc. Price v. Janssen Pharmaceuticals, Inc.		
11111	3	10 03033	Tite v. varissen i narmaeeaticais, me.		